PAREXEL - Josh Schultz Discusses the Importance of Late Phase Partnerships
Late phase partnerships are important to our clients for three major reasons. The first one is that we have an incredible demand from various stakeholders, providers, payers, physicians for evidence and we need to deliver that in a cost effective manner. The second reason is that we have huge lessons learned from our industry and from other industries with regard to the right way to structure relationships to get the maximum value and these work well beyond the transactional approaches that we’ve used in the past. The third one is that there’s a huge variety of different opportunities to achieve trends in late phase that are very difficult to use in a transactional environment that can be used in partnerships. For example, access to data assets, use of mobile technologies, and different ways of structuring the study in the first place. PAREXEL is uniquely able to support our partners in late phase for three major reasons. The first one is that we have been leaders in the partnership space for decades and our ability and knowledge of the principles of partnership allow us to apply best practices to this unique area. The second reason is that we have a global reach that is almost unmatched in the industry. That global reach allows us to support our clients’ late phase needs really anywhere on the globe that they want to go. The third is that we have a tremendous set of capabilities at PAREXEL across the whole spectrum of late phase, including interventional studies, observational studies, health economics, patient safety, etymological consulting and all the other technologies and skills that are needed to help provide full service support to our customers.